Access Bio signs $3.73 million contract to supply flu and COVID-19 home tests to P&G subsidiary
PG•Access Bio signed a KRW 4.97 billion contract to supply combination Flu A, Flu B and COVID-19 home tests to Procter & Gamble Manufacturing for the U.S. market. The contract equals 15.89% of Access Bio’s 2025 consolidated revenue and runs from October 15, 2026, through October 14, 2027.
1. Contract details
Access Bio signed a KRW 4.97 billion supply contract with Procter & Gamble Manufacturing on October 20, 2026. It covers Flu A, Flu B and COVID-19 combination home tests for the U.S. market, with supply scheduled from October 15, 2026, through October 14, 2027; the value represents 15.89% of Access Bio’s 2025 consolidated revenue.
